MedPath

Tiotropium

Generic Name
Tiotropium
Brand Names
Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
Drug Type
Small Molecule
Chemical Formula
C19H22NO4S2
CAS Number
186691-13-4
Unique Ingredient Identifier
0EB439235F
Background

Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.

Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than ipratropium.

Tiotropium was granted FDA approval on 30 January 2004.

Indication

Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old. A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.

Associated Conditions
Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
Clinical Trials
Related News

Boehringer Ingelheim and Cue Biopharma Partner on Novel B Cell-Targeting Therapy for Autoimmune Diseases

• Boehringer Ingelheim and Cue Biopharma have formed a strategic partnership to develop CUE-501, a first-in-class bispecific therapy designed to selectively deplete disease-causing B cells in autoimmune conditions. • The collaboration includes $12 million upfront payment to Cue Biopharma, with potential milestone payments reaching $345 million plus royalties, significantly strengthening Boehringer's immunology pipeline. • CUE-501 utilizes Cue's proprietary Immuno-STAT™ platform to engage virus-specific memory T cells against targeted B cells, potentially offering superior efficacy and safety compared to existing B cell-depleting therapies.

Dupixent Approved for COPD: A New Era in Targeted Therapy

• The FDA has approved Dupixent (dupilumab) for COPD, marking the first targeted therapy addressing the IL-4 and IL-13 pathways linked to type 2 inflammation. • Clinical trials demonstrated Dupixent reduced moderate-to-severe COPD exacerbations by 30% over 52 weeks, with significant improvements in lung function. • COPD affects approximately 44 million people in the 7MM, with the market expected to reach USD 16 billion in 2023 and grow at a CAGR of 5% by 2034. • Emerging therapies like itepekimab, benralizumab, tezepelumab and mepolizumab are in development, poised to further transform the COPD treatment landscape.

Verona Pharma's Ensifentrine (Ohtuvayre) Approved for COPD Maintenance Treatment

• Verona Pharma's Ensifentrine, marketed as Ohtuvayre, received FDA approval on June 26th for maintenance treatment of chronic obstructive pulmonary disease (COPD). • Ohtuvayre, a first-in-class dual PDE3 and PDE4 inhibitor, combines bronchodilator and anti-inflammatory properties into a single compound. • Verona Pharma is also developing Ensifentrine for other respiratory indications, including Non-Cystic Fibrosis Bronchiectasis (NCFBE), with a Phase 2 study initiating this quarter. • The initial list price for Ohtuvayre is $2,950 per month, with the company focusing on high-volume prescribing healthcare providers and securing Medicare and insurance coverage.

Ensifentrine Shows Promise in Improving Lung Function and COPD Symptoms

• A Phase 2b trial of ensifentrine demonstrated statistically significant improvements in lung function in COPD patients. • The study also met clinically relevant secondary endpoints, showing improvements in COPD symptoms. • Ensifentrine is a first-in-class, inhaled, dual inhibitor of phosphodiesterase 3 and 4, acting as both an anti-inflammatory and bronchodilator. • Verona Pharma anticipates an End-of-Phase 2 meeting with the FDA to discuss Phase 3 program design.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy